A longitudinal study across two major U.S. health databases found nucleoside reverse transcriptase inhibitors to be associated with reduced Alzheimer's disease incidence.
FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.
In a 72-week study of hepatitis B patients, researchers found liver stiffness declines were driven by improved inflammation, not actual fibrosis regression.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
Stigmatizing language on transplant websites may deter patients with alcohol use disorder and alcohol-associated liver disease from seeking necessary medical care.